The renal pathology in clinical trials of Cis-platinum (II) diamminedichloride

Platinum Compounds: a New Class of Potent Antitumour Agents

1969 • 3,785 citations

Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).

1973 • 430 citations

The successful regression of large solid sarcoma 180 tumors by platinum compounds.

1970 • 372 citations

Improvement of Cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model

1977 • 260 citations

Interaction of cis-dichlorodiammineplatinum (II) with DNA

1971 • 157 citations

Clinical trials of cis-diamminedichloroplatinum (NSC-119875).

1973 • 133 citations

cis-Dichlorodiammineplatinum(II) (NSC-119 875): Preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice

1973 • 131 citations

Cytological study of the effect of cyclophosphamide on the epithelium of the urinary bladder in man

1964 • 129 citations

Antileukaemic and Nephrotoxic Properties of Platinum Compounds

1971 • 113 citations

Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat.

1971 • 106 citations

Pathology of high dose intermittent cyclophosphamide therapy

1975 • 100 citations

Inhibition of Dunning asc itic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875).

1970 • 62 citations

Platinum nephrotoxicity

1974 • 55 citations

Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in combination with cyclophosphamide (NSC-26271) in the treatment of human malignancies.

1975 • 29 citations

Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and cis-platinum (II) diaminedichloride (NSC 119875)

1974 • 20 citations

Enhanced survival response of l1210 leukemic mice to a single combin- ation treatment with cis-platinum(ii) diamminodichloride (cis-pt ii. Nsc-119875) plus cyclophosphamide (cy, nsc-26271). Abstr.

1971 • 6 citations